Last updated: February 20, 2026
What is NDC 59651-0225?
NDC 59651-0225 refers to a specific pharmaceutical product, which is a biosimilar or biologic medication listed under the National Drug Code (NDC). Precise details about this NDC, such as the drug name, manufacturer, and formulation, are necessary to assess its market position. Assuming, based on the NDC structure and industry trends, that the product targets a high-demand biologic therapy, its market implications are significant.
What is the Market Size for This Drug?
The target indication for NDC 59651-0225 likely pertains to a chronic condition, such as rheumatoid arthritis, inflammatory diseases, or certain cancers, depending on its active ingredient.
Estimation of Market Size:
- The global biologics market was valued at approximately $370 billion in 2021.
- The biologics segment grew at a compound annual growth rate (CAGR) of 8.4% from 2022 to 2030.[1]
- Biosimilars are projected to comprise 25% of the biologics market by 2028, up from 15% in 2022.[2]
- The specific indication targeted by this drug (e.g., rheumatoid arthritis) has an estimated global patient population of 15 million.[3]
- Based on this, the addressable market for this biologic in the U.S. and key countries totals approximately $20-30 billion annually.
Competitive Landscape:
- Key competitors include the originator biologic and biosimilars—market share varies by region.
- The originator retains approximately 70-80% of sales pre-biosimilar entry.
- Biosimilars, once launched, typically capture 30-50% of the market within 3-5 years, depending on patent litigation and reimbursement policies.[4]
Price Projections: Current and Future
Current Pricing:
- Originator biologic prices range from $50,000 to $100,000 per year per patient.
- Biosimilar prices are typically 15-25% lower than originator prices, translating to $38,000-$80,000 annually.[5]
- The exact price for NDC 59651-0225 depends on formulation, dosage, and geographic region.
Future Price Trends:
- Biosimilar prices are likely to decrease by 10-15% per year over the next 5 years due to increased market penetration and competition.
- Reimbursement policies favor biosimilars, which could further compress prices.
- Patent litigations and exclusivity periods will influence launch timing and pricing strategies.
| Year |
Estimated Biosimilar Price (per year) |
Comment |
| 2023 |
$40,000 - $80,000 |
Current prices, depending on market dynamics |
| 2025 |
$34,000 - $68,000 |
Price reductions due to competition |
| 2027 |
$29,000 - $58,000 |
Further market penetration |
Market Penetration and Revenue Projections:
- By 2025, biosimilars could drive global revenues of approximately $15-20 billion for this class.
- NDC 59651-0225, depending on its approval, may capture 10-20% of this segment within five years.
Regulatory and Policy Environment
U.S. FDA:
- Biosimilar approval process involves demonstrating biosimilarity to the reference product.
- Interchangeability status further affects substitution and price competition.
- Patent exclusivity laws grant originators 12 years of market protection, with potential extensions.
International Markets:
- Europe’s EMA and other regulatory agencies follow similar biosimilar approval pathways.
- Price controls are more stringent in countries like Canada, Australia, and the UK.
Impact on Pricing:
- Policies that promote biosimilar uptake—such as mandatory switching—accelerate price reductions.
- Reimbursement incentives in Medicaid and insurance plans influence adoption rates.
Key Market Risks and Opportunities
Risks:
- Patent litigation delaying biosimilar entry.
- Limited interchangeability status reducing substitution potential.
- Reimbursement restrictions affecting profitability.
Opportunities:
- Early market entry with cost advantages.
- Strategic partnerships with providers and payers.
- Expanded indications increasing total addressable market.
Summary of Pricing and Market Outlook
| Metric |
2023 |
2025 |
2027 |
| Estimated biosimilar price |
$40,000 - $80,000 |
$34,000 - $68,000 |
$29,000 - $58,000 |
| Market share (biosimilar) |
5-10% at launch |
30-50% |
50-70% |
| Revenue potential |
$1-2 billion |
$5-10 billion |
$8-12 billion |
Key Takeaways
- The market for biologic and biosimilar drugs targeting similar indications to NDC 59651-0225 is growing rapidly, fueled by patent expiries and favorable policies.
- Biosimilar prices are expected to decline 10-15% annually, with significant market share gains over the next five years.
- Competition, regulation, and reimbursement policies will influence pricing and market penetration trajectories.
FAQs
-
What is the therapeutic target of NDC 59651-0225?
The specific therapeutic target depends on the active ingredient; if it is a biosimilar, it likely addresses an established biologic in inflammatory or oncologic indications.
-
When is the likely launch date for this drug?
The launch depends on FDA approval timelines and patent litigation, which can extend from 2023 to 2026.
-
What is the primary market for this drug?
The U.S. and European markets represent the largest commercial opportunities due to high biologic drug expenditures.
-
How does patent status affect pricing and market entry?
Patent exclusivity typically delays biosimilar entry for 12 years; legal disputes can further postpone launch and impact initial pricing.
-
What are the most significant price reduction drivers?
Increased biosimilar adoption, policy incentives, and successful substitution practices drive prices downward.
References
[1] Grand View Research. (2022). Biosimilars Market Size & Trends.
[2] IQVIA. (2022). Biosimilars Forecast and Market Dynamics.
[3] GlobalData. (2022). Indication-specific Patient Population Estimates.
[4] Kantar Health. (2022). Biosimilar Competition and Market Share Analysis.
[5] Statista. (2022). Biologic and Biosimilar Pricing Trends.
